biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > BTI:TSXV: Announces $200,000 Non-Brokered Private Placement

<< Previous

Bullboard Posts

Next >>

Comment by fishtailon Jan 30, 2021 9:39am

165 Views

Post# 32427858

RE:RE:RE:RE:RE:RE:RE:RE:BTI:TSXV: Announces $200,000 Non-Brokered Private Placement

>> This $200,000.00 deal is most likely a follow up from the virtual investment conference previou

I agree and maybe someone informed with a personal connection to an area targeted by BTIs technologies. There are lots of investors in these biotechs who really understand the scientific possibilities, and who also like to focus where they have a personal experience.